<DOC>
	<DOCNO>NCT00782314</DOCNO>
	<brief_summary>We want evaluate efficacy Symbicort® Turbuhaler® ( formoterol/budesonide ) therapy asthma real life condition . For purpose include patient treated Symbicort® Turbuhaler® `` classical '' maintenance treatment approach well treat SMART approach .</brief_summary>
	<brief_title>Evaluating Symbicort Turbuhaler ( Formoterol/Budesonide ) Maintenance Reliever Therapy Asthma Daily Practice</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>patient diagnose persistent asthma treat Symbicort® Turbuhaler® line label nonpregnant female exist maintenance treatment Symbicort® Turbuhaler® 80 μg/4,5 μg , 160 μg/4,5 μg 320 μg/9 μg least 1 month exist SMART treatment Symbicort® Turbuhaler® 80 μg/4,5 μg 160 μg /4,5 μg least 1 month patient treat Symbicort® Turbuhaler® patient treat Symbicort® Turbuhaler® COPD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>asthma</keyword>
	<keyword>SMART</keyword>
	<keyword>Symbicort Turbuhaler</keyword>
	<keyword>asthma control</keyword>
</DOC>